NCT04421560 2026-02-20
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02315768 2025-09-15
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
Phase 1/2 Completed
NCT04522284 2023-03-29
PRECISE CURATE.AI Pilot Clinical Trial
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02356458 2022-03-11
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Terminated